

Amendments to the Claims:

Claims 1-37 (Cancelled)

Claim 38 (Previously Presented): A method for treating a cancer in a patient in need thereof comprising administering to said patient, concurrently or sequentially, a therapeutically effective amount of at least one indoleamine 2,3-dioxygenase (IDO) inhibitor and at least one chemotherapeutic agent, wherein said IDO inhibitor is methyl-TH-DL-trp.

Claim 39 (Previously Presented): The method of claim 38, wherein said at least one chemotherapeutic agent is selected from the group consisting of paclitaxel (Taxol®), cisplatin, docetaxel, carboplatin, vincristine, vinblastine, methotrexate, cyclophosphamide, CPT-11, 5-fluorouracil (5-FU), gemcitabine, estramustine, carmustine, adriamycin (doxorubicin), etoposide, arsenic trioxide, irinotecan, and epothilone derivatives.

Claim 40 (Withdrawn): The method of claim 39, wherein said at least one chemotherapeutic agent is paclitaxel.

Claim 41 (Cancelled)

Claim 42 (Cancelled)

Claim 43 (Original): The method of claim 38, wherein said at least one IDO inhibitor and said at least one chemotherapeutic agent are administered concurrently.

Claim 44 (Original): The method of claim 38, wherein said at least one IDO inhibitor and said at least one chemotherapeutic agent are administered sequentially.

Claim 45 (Original): The method of claim 44, wherein said at least one IDO inhibitor is administered before said at least one chemotherapeutic agent.

Claim 46 (Original): The method of claim 44, wherein said at least one chemotherapeutic agent is administered before said at least one IDO inhibitor.

Claim 47 (Previously Presented): The method of claim 38, wherein said cancer is selected from the group consisting of cancers of the prostate, colorectum, pancreas, cervix, stomach, endometrium, brain, liver, bladder, ovary, testis, head, neck, skin, mesothelial lining, white blood cell, esophagus, breast, muscle, connective tissue, lung, adrenal gland, thyroid, kidney, or bone; melanoma, basal carcinoma, lymphoma, leukemia, small-cell lung carcinoma, non-small-cell lung carcinoma, glioblastoma, mesothelioma, renal cell carcinoma, gastric carcinoma, sarcoma, choriocarcinoma, cutaneous basocellular carcinoma, and testicular seminoma.

Claims 48-54 (Cancelled)

Claim 55 (Previously Presented): The method of claim 47, wherein said cancer is selected from the group consisting of ovarian cancer, leukemia, melanoma, breast cancer, colorectal cancer, and lung cancer.

Claim 56 (Previously Presented): The method of claim 55, wherein said cancer is breast cancer.

Claim 57 (Currently Amended): A method for treating a cancer in a patient in need thereof comprising administering to said patient, concurrently or sequentially, a therapeutically effective amount of at least one indoleamine 2,3-dioxygenase (IDO) inhibitor and at least one chemotherapeutic agent, wherein said IDO inhibitor is 1-methyl-DL-tryptophan, wherein

said cancer is breast cancer, and wherein said
chemotherapeutic agent is cisplatin.

Claim 58 (Cancelled)

Claim 59 (Previously Presented): The method of claim 57,
wherein said at least one IDO inhibitor and said at least one
chemotherapeutic agent are administered concurrently.

Claim 60 (Previously Presented): The method of claim 57,
wherein said at least one IDO inhibitor and said at least one
chemotherapeutic agent are administered sequentially.

Claim 61 (Previously Presented): The method of claim 60,
wherein said at least one IDO inhibitor is administered before
said at least one chemotherapeutic agent.

Claim 62 (Previously Presented): The method of claim 60,
wherein said at least one chemotherapeutic agent is
administered before said at least one IDO inhibitor.

Claims 63-66 (Cancelled)